This week, cannabis coverage focused on regulatory developments, commercial testing technology, and clinical research into therapeutic applications and safety monitoring.
Monday, March 16, 2026 — top 4 across News, Studies, Policy, and Memes
A March 16, 2026 news roundup featuring five cannabis stories, including research on whether cannabis use accelerates mental decline in older adults.
AM News Update: March 16, 2026 →Cannabix Technologies has launched a commercial marijuana breath test device that provides rapid, non-invasive detection of cannabis use for clinical and impairment assessment applications.
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) →Avicanna is sponsoring a University of Calgary clinical trial to determine safe and effective THC dosing for therapeutic use in patients.
Avicanna announces sponsorship of University of Calgary THC dose finding clinical trial →This clinical resource examines cannabis use among teenage and young adult drivers, focusing on safety concerns relevant to pediatric and mental health clinicians.
Driving habits of teens and young adults | National Poll on Children’s Health →A March 2026 research update summarizing 20 cannabis studies from PubMed, including a phase 3 trial of Cannabis sativa extract for chronic low back pain.
AM Study Update: March 16, 2026 →This piece reviews clinical evidence on cannabinoid use in pediatric patients across various medical conditions, noting data quality varies across different study types.
Endocannabinoid System Research: Cannabinoids in Children →A phase 3 clinical trial tested full-spectrum cannabis extract VER-01 versus placebo in 820 adults with chronic low back pain over 12 weeks, with extended follow-up to one year.
endocannabinoid system clinical research: Cannabis for Back Pain →A March 2026 research update presenting 20 cannabis studies from PubMed, including a phase 3 trial of Cannabis sativa extract for chronic low back pain.
AM Study Update: March 16, 2026 →The DEA temporarily placed bromazolam, a benzodiazepine analog, in Schedule I, as reported in a March 16, 2026 policy update covering 20 federal regulatory items.
AM Policy Update: March 16, 2026 →The AM Policy Update from March 16, 2026 covers 20 federal regulatory items, including the DEA’s temporary placement of bromazolam into Schedule I of controlled substances.
AM Policy Update: March 16, 2026 →The DEA temporarily scheduled bromazolam as a Schedule I controlled substance, among 20 federal regulatory updates reported on March 15, 2026.
AM Policy Update: March 15, 2026 →The DEA temporarily placed bromazolam, a benzodiazepine analog, into Schedule I of controlled substances due to emerging safety and abuse concerns.
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I →This article discusses how cannabis cannabinoid profiles are more important than botanical classifications like indica, sativa, or hybrid varieties.
What kind of tree is this? →A clinical anecdote about a patient consultation where discussion of cannabis terpene profiles became overly focused on geographic origin details.
Hello everyone, greetings from Morocco →A post asks whether cannabis with visible trichomes but a high leaf-to-flower ratio is worth smoking, questioning the balance between potency indicators and trimming quality.
Settle the debate. Would you smoke this or is it too leafy? →The piece humorously critiques unfounded medical claims about cannabis, specifically calling out the assertion that it cures cancer without scientific evidence.
What’s a stoner opinion that would have you like this? →Digest-Level Clinical Commentary
Clinical Reflection on Current Cannabis Medicine Landscape The digest reflects a field in transitional maturity, where legitimate clinical research on cannabinoid therapeutics, particularly for pain management and dose optimization, now coexists alongside ongoing policy development and emerging detection technologies that will increasingly shape clinical practice documentation and medicolegal considerations. The prominence of regulatory updates and impaired driving surveillance suggests that cannabis medicine practitioners must now attend equally to evidence-based pharmacology and to the governance frameworks that will govern clinical decision-making and patient safety monitoring. Notably, the inclusion of non-clinical content about product aesthetics underscores the persistent challenge of elevating cannabis medicine discourse beyond consumer-level heuristics toward standardized clinical assessment, despite the field’s demonstrable progress in rigorous Phase 3 trial design and endocannabinoid system research.
This digest reflects the field’s concurrent focus on clinical evidence development and regulatory infrastructure around cannabis therapeutics. Several items highlight substantive research efforts, including dose-finding trials and phase 3 efficacy data for specific conditions like back pain, alongside emerging diagnostic tools such as breath testing for impairment detection. The inclusion of lighter content suggests the digest casts a wide net, though the core themes center on the tension between accumulating clinical data and the evolving regulatory landscape that will ultimately determine how cannabis products are integrated into evidence-based practice.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: